The IP6K Inhibitor LI-2242 Ameliorates Diet-Induced Obesity, Hyperglycemia, and Hepatic Steatosis in Mice by Improving Cell Metabolism and Insulin Signaling
Obesity and nonalcoholic fatty liver disease (NAFLD) are global health concerns, and thus, drugs for the long-term treatment of these diseases are urgently needed. We previously discovered that the inositol pyrophosphate biosynthetic enzyme IP6K1 is a target in diet-induced obesity (DIO), insulin re...
Main Authors: | Sandip Mukherjee, Molee Chakraborty, Jake Haubner, Glen Ernst, Michael DePasquale, Danielle Carpenter, James C. Barrow, Anutosh Chakraborty |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-05-01
|
Series: | Biomolecules |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-273X/13/5/868 |
Similar Items
-
Whole Body <i>Ip6k1</i> Deletion Protects Mice from Age-Induced Weight Gain, Insulin Resistance and Metabolic Dysfunction
by: Sarbani Ghoshal, et al.
Published: (2022-02-01) -
Pleiotropic actions of IP6K1 mediate hepatic metabolic dysfunction to promote nonalcoholic fatty liver disease and steatohepatitis
by: Sandip Mukherjee, et al.
Published: (2021-12-01) -
Branching bandits and Klimov's problem : achievable region and side constraints
Published: (2003) -
Ube4A maintains metabolic homeostasis and facilitates insulin signaling in vivo
by: Sandip Mukherjee, et al.
Published: (2023-09-01) -
Regulatory Treatment of IP Transport and Services
by: Sirbu, Marvin, et al.
Published: (2002)